Use of fluorquinolones is associated with a reduced risk of coronary heart disease in diabetes mellitus type 2 patients

European Heart Journal

Volumn 23, Issue 20, 2002, Pages 1575-1579

  Erkens, J A ^a,b   Klungel, O H ^a   Herings, R M C ^a,c   Stolk, R P ^b   Spoelstra, J A ^a,b   Grobbee, D E ^b   Leufkens, H G M ^a  

^a UTRECHT UNIVERSITY   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

Author keywords

Antibiotic drugs; Coronary heart disease; Diabetes mellitus type 2; Epidemiology

Indexed keywords

ANTIBIOTIC AGENT; CEPHALOSPORIN DERIVATIVE; MACROLIDE; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULFONAMIDE; TETRACYCLINE DERIVATIVE; TRIMETHOPRIM;

ADULT; AGED; ANTIBIOTIC THERAPY; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG USE; FEMALE; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; NETHERLANDS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

AGED; CASE-CONTROL STUDIES; CONTROL GROUPS; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; FLUOROQUINOLONES; HUMANS; MALE; MEDICAL RECORD LINKAGE; RISK;

EID: 0036797616     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2002.3173     Document Type: Article

References (38)

1. Siscovick DS, Schwartz SM, Corey L et al. Chlamydia pneumoniae, herpes simplex virus type 1, and cytomegalovirus and incident myocardial infarction and coronary heart disease death in older adults: The Cardiovascular Health Study. Circulation 2000; 102: 2335-40.
2. Cook PJ, Honeybourne D, Lip GY, Beevers DG, Wise R, Davies P. Chlamydia pneumoniae antibody titers are significantly associated with acute stroke and transient cerebral ischemia: the West Birmingham Stroke Project. Stroke 1998; 29: 404-10.
3. Fagerberg B, Gnarpe J, Gnarpe H, Agewall S, Wikstrand J. Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease: A prospective study in middle-aged to elderly men with treated hypertension. Stroke 1999; 30: 299-305.
4. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997; 350: 430-6.
5. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96: 404-7.
6. Kiechl S, Egger G, Mayr M et al. Chronic infections and the risk of carotid atherosclerosis: prospective results from a large population study. Circulation 2001; 103: 1064-70.
7. Sander D, Winbeck K, Klingelhofer J, Etgen T, Conrad B. Enhanced progression of early carotid atherosclerosis is related to chlamydia pneumoniae (Taiwan Acute Respiratory) seropositivity. Circulation 2001; 103: 1390-5.
8. Elkind MS, Lin IF, Grayston JT, Sacco RL. Chlamydia pneumoniae and the risk of first ischemic stroke: The Northern Manhattan Stroke Study. Stroke 2000; 31: 1521-5.
9. Davidson M, Kuo CC, Middaugh JP et al. Confirmed previous infection with Chlamydia pneumoniae (TWAR) and its presence in early coronary atherosclerosis. Circulation 1998; 98: 628-33.
10. Herings RM, Leufkens HG, Vandenbroucke JP. Acute myocardial infarction and prior antibiotic use. JAMA 2000; 284: 2998-9.
11. Meier CR, Derby LE, Jick SS, Vasilakis C, Jick H. Antibiotics and risk of subsequent first-time acute myocardial infarction. JAMA 1999; 281: 427-31.
12. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. Lancet 1997; 350: 404-7.
13. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study. Eur Heart J 1999; 20: 121-7.
14. Anderson JL, Muhlestein JB, Carlquist J et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation 1999; 99: 1540-7.
15. Lee HZ, Lin WC, Yeh FT, Wu CH. 2-Phenyl-4-quinolone prevents serotonin-induced increases in endothelial permeability to albumin. Eur J Pharmacol 1998; 354: 205-13.
16. Menschik M, Neumuller J, Steiner CW et al. Effects of ciprofloxacin and ofloxacin on adult human cartilage in vitro. Antimicrob Agents Chemother 1997; 41: 2562-5.
17. Bini A, Mann KG, Kudryk BJ, Schoen FJ. Noncollagenous bone matrix proteins, calcification, and thrombosis in carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol 1999; 19: 1852-61.
18. Wheat LJ. Infection and diabetes mellitus. Diabetes Care 1980; 3: 187-97.
19. Joshi N, Caputo GM, Weitekamp MR, Karchmer AW. Infections in patients with diabetes mellitus. N Engl J Med 1999; 341: 1906-12.
20. Wagenknecht LE, D'Agostino RB, Jr., Haffner SM, Savage PJ, Rewers M. Impaired glucose tolerance, type 2 diabetes, and carotid wall thickness: The Insulin Resistance Atherosclerosis Study. Diabetes Care 1998; 21: 1812-8.
21. Jackson LA, Smith NL, Heckbert SR, Grayston JT, Siscovick DS, Psaty BM. Lack of association between first myocardial infarction and past use of erythromycin, tetracycline, or doxycycline. Emerg Infect Dis 1999; 5: 281-4.
22. Herings RM, Bakker A, Stricker BH, Nap G. Pharmacomorbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health 1992; 46: 136-40.
23. EGRET for Windows. Cambridge MA; 1999.
24. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992; 45: 197-203.
25. Clark DO, Von Korff M, Saunders K, Baluch WM, Simon GE. A chronic disease score with empirically derived weights. Med Care 1995; 33: 783-95.
26. Hammerschlag MR. Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae. Antimicrob Agents Chemother 1994; 38: 1873-8.
27. Hammerschlag MR, Qumei KK, Roblin PM. In vitro activities of azithromycin, clarithromycin, L-ofloxacin, and other antibiotics against Chlamydia pneumoniae. Antimicrob Agents Chemother 1992; 36: 1573-4.
28. Ostergaard L, Sorensen HT, Lindholt J et al. Risk of hospitalization for cardiovascular disease after use of macrolides and penicillins: a comparative prospective cohort study. J Infect Dis 2001; 183: 1625-30.
29. Neumann F, Kastrati A, Miethke T et al. Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): A randomised, double-blind, placebocontrolled trial. Lancet 2001; 357: 2085-9.
30. Jackson LA, Smith NL, Heckbert SR, Grayston JT, Siscovick DS, Psaty BM. Past use of erythromycin, tetracycline, or doxycycline is not associated with risk of first myocardial infarction. J Infect Dis 2000; 181 (Suppl 3): S563-5.
31. Byrne GI, Ouellette SP, Wang Z et al. Chlamydia pneumoniae expresses genes required for DNA replication but not cytokinesis during persistent infection of HEp-2 cells. Infect Immun 2001; 69: 5423-9.
32. Witteman JC, Kannel WB, Wolf PA et al. Aortic calcified plaques and cardiovascular disease (the Framingham Study). Am J Cardiol 1990; 66; 1060-4.
33. Libby P, Egan D, Skarlatos S. Roles of infectious agents in atherosclerosis and restenosis: An assessment of the evidence and need for future research. Circulation 1997; 96: 4095-103.
34. Ridker PM, Kundsin RB, Stampfer MJ, Poulin S, Hennekens CH. Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. Circulation 1999; 99: 1161-4.
35. Lip GY, Beevers DG. Can we treat coronary artery disease with antibiotics? Lancet 1997; 350: 378-9.
36. Grayston JT. Antibiotic treatment of Chlamydia pneumoniae for secondary prevention of cardiovascular events. Circulation 1998; 97: 1669-70.
37. Folsom AR. Antibiotics for prevention of myocardial infarction? Not yet! JAMA 1999; 281: 461-2.
38. Meier CR. Antibiotics in the prevention and treatment of coronary heart disease. J Infect Dis 2000; 181 (Suppl 3): S558-62.